A Phase I/Ib, Open-label, Multi-center Dose-escalation and Dose-expansion Study of the Safety and Tolerability of Intra-tumorally Administered LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 19 Dec 2018
At a glance
- Drugs LHC-165 (Primary) ; Spartalizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 04 Oct 2018 Planned End Date changed from 14 Aug 2019 to 20 Dec 2021.
- 04 Oct 2018 Planned primary completion date changed from 27 Jun 2019 to 16 Apr 2021.
- 05 Jun 2018 Planned End Date changed from 7 Feb 2021 to 14 Aug 2019.